Načítá se...
Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey
INTRODUCTION: Omalizumab is a current treatment option for IgE-associated dermatoses, such as urticaria and atopic dermatitis. AIM: To evaluate the clinical and laboratory findings of patients with chronic urticaria and atopic dermatitis who received omalizumab. MATERIAL AND METHODS: This study was...
Uloženo v:
| Vydáno v: | Postepy Dermatol Alergol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Termedia Publishing House
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6986296/ https://ncbi.nlm.nih.gov/pubmed/31998003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/ada.2019.91424 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|